 | Up a level |
Jerusalem, G; Farah, S; Courtois, A; Chirgwin, J; Aebi, S; Karlsson, P; Neven, P; Hitre, E; Graas, M P; Simoncini, E; Abdi, E; Kamby, C; Thompson, A; Loibl, S; Gavilá, J; Kuroi, K; Marth, C; Müller, B; O'Reilly, S; Gombos, A; ... (2021). Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of oncology, 32(10), pp. 1256-1266. Elsevier 10.1016/j.annonc.2021.07.017
Francis, PA; Pagani, O; Fleming, GF; Walley, BA; Colleoni, M; Láng, I; Gómez, HL; Tondini, C; Ciruelos, E; Burstein, HJ; Bonnefoi, HR; Bellet, M; Martino, S; Geyer, Jr. CE; Goetz, MP; Stearns, V; Pinotti, G; Puglisi, F; Spazzapan, S; Climent, MA; ... (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England journal of medicine NEJM, 379(2), pp. 122-137. Massachusetts Medical Society MMS 10.1056/NEJMoa1803164
Ruhstaller, T; Thuss-Patience, P; Hayoz, S; Schacher, S; Knorrenschild, J R; Schnider, A; Plasswilm, Ludwig; Budach, W; Eisterer, W; Hawle, H; Mariette, C; Hess, V; Mingrone, W; Montemurro, M; Girschikofsky, M; Schmidt, S C; Bitzer, M; Bedenne, L; Brauchli, P and Stahl, M (2018). Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Annals of oncology, 29(6), pp. 1386-1393. Oxford University Press 10.1093/annonc/mdy105
Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, Jürg; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, Manuela; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; von Moos, R; Zaman, K; ... (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of oncology, 28(2), pp. 305-312. Oxford University Press 10.1093/annonc/mdw622
Rochlitz, C; Ruhstaller, T; Lerch, S; Spirig, C; Huober, J; Suter, T; Bühlmann, M; Fehr, M; Schönenberger, A; von Moos, R; Winterhalder, R; Rauch, D; Müller, A; Mannhart-Harms, M; Herrmann, R; Cliffe, B; Mayer, M; Zaman, K; Swiss Group for Clinical Cancer Research, (SAKK) (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, 22(1), pp. 80-5. Oxford: Oxford University Press 10.1093/annonc/mdq319
Ruhstaller, T; Widmer, L; Schuller, J C; Roth, A; Hess, V; Mingrone, W; von Moos, R; Borner, M; Pestalozzi, B C; Balmermajno, S; Köberle, D; Terraciano, L; Schnider, A; Bodis, S; Popescu, R (2009). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology, 20(9), pp. 1522-8. Oxford: Oxford University Press 10.1093/annonc/mdp045
Borner, M; Koeberle, D; Von Moos, R; Saletti, P; Rauch, D; Hess, V; Trojan, A; Helbling, D; Pestalozzi, B; Caspar, C; Ruhstaller, T; Roth, A; Kappeler, A; Dietrich, D; Lanz, D; Mingrone, W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology, 19(7), pp. 1288-92. Oxford: Oxford University Press 10.1093/annonc/mdn058
Ribi, K; Bernhard, J; Rufibach, K; Thürlimann, B; von Moos, R; Ruhstaller, T; Glaus, A; Böhme, C (2007). Endocrine symptom assessment in women with breast cancer: what a simple "yes" means. Supportive care in cancer, 15(12), pp. 1349-56. Berlin: Springer 10.1007/s00520-007-0258-3
Herrmann, R; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B; Köhne, CH; Mingrone, W; Stemmer, SM; Tàmas, K; Kornek, GV; Koeberle, D; Cina, S; Bernhard, J; Dietrich, D; Scheithauer, W; ... (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology, 25(16), pp. 2212-7. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.09.0886
